Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Servier Builds Oncology Portfolio With New Deal
The France-based pharmaceutical company Servier is back with a new deal, adding Agios Pharmaceuticals, Inc.‘s (NASDAQ: AGIO) oncology portfolio for $1.8 billion upfront in cash. The portfolio consists of Agios’ commercial, clinical and research-stage oncology product line, which includes Tibsovo, a treatment for adults with IDH1-mutant relapsed or refractory acute myeloid leukemia, and additional oncology pipeline and clinical programs. The deal also includes Agios’ co-commercialization responsibilities for Bristol Myers Squibb’s (NYSE: BMY) IDHIFA and certain clinical development activities within the IDHIFA development program. In addition to the upfront payment, Servier will pay Agios... Read More »
Cerner Corporation adds Kantar Health
After no updates in the M&A market for more than five years, according to results in our Healthcare Deal Database, Cerner Corporation (NASDAQ: CERN) is back with a new deal. The digital health company announced it is acquiring Kantar Health for $375 million in cash from Kantar Group. Kantar Group is a portfolio company of Bain Capital. Kantar Health is a data analytics and real-world evidence and commercial research consultancy serving the life science industry. Cerner offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs. Kantar Health’s proprietary... Read More »
BayMark Health Announces Three Deals
BayMark Health Services announced a trio of deals last week alone, doubling its transaction count for 2020, based on results from Healthcare Deals Database. With the backing of private equity firm Webster Equity Partners, the nationwide behavioral health provider acquired three new providers across three states for an undisclosed sum. For the first deal, BayMark Health acquired Portland, Maine- based Liberty Bay Recovery Center, a residential treatment facility (59 beds) that offers treatment for a variety of addictions including not only opioids but also alcohol, cocaine, methamphetamine, prescription drugs and other substances. It provides multiple levels of care including residential,... Read More »
Royal Philips Buys BioTelemetry
The medical device giant Royal Philips (NYSE: PHG) is back with a new deal, adding BioTelemetry, Inc. (NYSE: BEAT). The deal is valued at $2.8 billion, consisting of $72.00 per share in cash, or a 16.5% premium to BEAT’s closing price on December 17, 2020. BioTelemetry, formerly known as CardioNet, is a leading provider of remote cardiac diagnostics and monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing for healthcare and clinical research customers. BioTelemetry generated an annualized 2020 revenue of $458 million and annualized 2020 EBITDA of $92.3 million. The acquisition is a strong fit with... Read More »
Tenet Healthcare Sells Urgent Care Business
Tenet Healthcare Corporation (NYSE: THC) is having a busy holiday season. Early in December, the Texas-based health system purchased a portfolio of 45 ambulatory surgery centers (ASCs) from SurgCenter Development for $1.1 billion. Now, Tenet Healthcare is unloading a bulk of its urgent care platform in a deal valued at $80 million in order to focus on its ASC business. FastMed Urgent Care, backed by ABRY Partners and BlueMountain Capital Management, is buying Tenet’s platform, which is operated under the CareSpot and MedPost brands and managed by Tenet’s United Surgical Partners International subsidiary. The platform has 87 centers in Arizona and Texas. Tenet... Read More »
Health Care M&A Deals, December 18, 2020
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is AstraZeneca plc’s acquisition of Alexion Pharmaceuticals, Inc. for $39 billion. Alexion is a global biopharmaceutical company that has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. Alexion’s expertise... Read More »
What a Year It Was for Hospital M&A
The U.S. hospital system has had a stress-filled year, to say the least. By mid-December 2020, the nation’s death toll from the coronavirus topped 300,000 and daily hospitalizations closed in on 11,000. Front-line healthcare workers began receiving the Pfizer-BioNtech vaccine and Dr. Anthony Fauci, the nation’s top infectious disease expert, told MSNBC in an interview that the timeline for a return to normalcy stretched well into 2021. Not surprisingly, the hospital merger and acquisition landscape shifted, but it didn’t buckle. Overall, deals for hospitals are down 26% through mid-December (73 vs. 99 in 2019). For U.S. hospitals, deal volume dropped 16% (66 U.S. deals... Read More »
PointClickCare Technologies Adds Collective Medical
PointClickCare Technologies Inc. announced last week it is acquiring Collective Medical in an effort to more than double its platform size. PointClickCare Technologies is a software platform supporting a network of more than 21,000 skilled nursing facilities, senior living communities and home health agencies. It is backed by JMI Equity and Dragoneer Investment Group. Collective Medical is a leading real-time care notification, activation, and collaboration platform. The company’s platform collects data from electronic health records (EHRs) and health information exchanges to help providers make informed decisions. Sources cited in Business Insider value the merger at approximately... Read More »
AstraZeneca Buys Alexion In $39 Billion-Mega Deal
The global pharmaceutical giant AstraZeneca plc (NYSE: AZN) is back with its fifth deal of the year, and its biggest one at that. AstraZeneca is buying Boston, Massachusetts-based Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for $39 billion. Alexion is a global biopharmaceutical company that has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. According to the terms of the agreement, Alexion shareholders will receive $60 cash and 2.1243 AstraZeneca American Depositary Shares (ADS) per share (each ADS equals 1/2 AZN share). Based on AstraZeneca’s... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
